| Revenue Growth | R&S revenue grew 1.4% to $22.9M; service revenue fell to $203k. |
|---|---|
| Mgmt Confidence | Accountable for shortfall; taking 'prudent' approach to Q4 and 2027 recovery. |
| Demand Visibility | Six to nine-month patient pathway; seeing recovery in large accounts in Q4. |
| Margin Trends | Adjusted gross margin 84.8%, up 200 bps due to labor absorption. |
| Op. Leverage | Adjusted OPEX decreased 7% to $19.2M; managing spending while investing commercially. |
| Pricing Power | CMS increased hospital outpatient payment rate for R&S replacements by 11%. |
| Vol vs Price | Growth impacted by procedural scheduling delays and staffing issues at centers. |
| Segment Growth | R&S system revenue $22.9M; service revenue $0.2M. |
| New Clients | Reached new high in active prescribers; expanding medium-sized 'good to great' accounts. |
| Capex & Debt | Ended quarter with $49.5M cash; long-term borrowings total $59.2M. |
| Regulatory | IGE PMA amendment submission by year-end; potential approval mid-2027. |
| Commentary | Strategic shift from SEEG distribution caused temporary loss of routine OR presence. |
| New Launches | Remote care submitted to FDA; Aurora study for adolescent focal epilepsy initiated. |
Growth
Total revenue $23.1M, down 1.1%; R&S system revenue $22.9M, up 1.4% year-over-year.
Outlook
Guiding 2027 R&S revenue growth to 15%, accelerating to 20% exit rate.
Risks
Management pivoted to 'local market factors' when pressed on competition and customer concentration risks.
The company's earnings call, NASDAQ: NPCE, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
NeuroPace Inc: key numbers
- Share price
- $7.97Close, Nov 16
- Market cap
- $275M
- Shares outstanding
- 34.45MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from NeuroPace Inc
All →NeuroPace Q3 2026 Results: Net Loss of $3.3M, Loss Narrows
NeuroPace reported a decrease in total assets from $105.6 million at the end of 2025 to $94.8 million as of September 30, 2026, primarily driven by a reduction in cash and short-term investments. The company maintains a significant accumulated deficit of $568.6 million and expects to lose its emerging growth company status on December 31, 2026.
- Key figure
- Net loss $3.3M
NeuroPace Financial Results
NeuroPace reported Q3 2026 total revenue of $23.1 million, missing internal expectations due to commercial execution issues and field organization disruption. The company revised its full-year 2026 revenue guidance downward to $91-$92 million while advancing its innovation pipeline, including an FDA submission for NeuroPace Remote Care.
- Term
- Q3 2026
“Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates. The shortfall was concentrated in several of our largest accounts and reflected isolated account-level issues and changes to our field organization that created more disruption than anticipated.”
Joel Becker, President and Chief Executive Officer of NeuroPace
“Our innovation pipeline represents one of the most significant opportunities ahead for NeuroPace, combining potential indication expansion with capabilities that can make RNS therapy more accessible, efficient and personalized.”
Joel Becker, President and Chief Executive Officer of NeuroPace